心脉医疗(688016) - 2021 Q1 - 季度财报

Financial Performance - Operating income rose by 99.07% to CNY 197,465,973.72 year-on-year[12] - Net profit attributable to shareholders increased by 70.96% to CNY 101,685,449.02 compared to the same period last year[12] - Net profit for Q1 2021 rose by 70.96% to ¥101,685,449.02 from ¥59,479,274.72 in the same period last year[26] - The company's total profit for Q1 2021 was ¥118,653,048.74, marking a 70.79% increase from the previous year[26] - Total revenue for Q1 2021 reached ¥197,465,973.72, a 99.3% increase from ¥99,193,139.59 in Q1 2020[41] - Operating profit for Q1 2021 was ¥118,635,410.69, up 70.8% from ¥69,473,073.96 in Q1 2020[43] - The diluted earnings per share increased by 69.88% to CNY 1.41[12] - Basic and diluted earnings per share for Q1 2021 were both ¥1.41, compared to ¥0.83 in Q1 2020[45] Assets and Liabilities - Total assets increased by 11.60% to CNY 1,535,717,952.63 compared to the end of the previous year[12] - Total assets increased to CNY 1,544,204,715.69 as of March 31, 2021, compared to CNY 1,383,282,091.97 at the end of 2020, representing a growth of approximately 11.6%[39] - Current assets totaled CNY 1,226,788,881.44, up from CNY 1,087,529,223.50, indicating an increase of about 12.8%[35] - Total liabilities increased significantly, with accounts payable rising by 74.67% to ¥31,144,000.54, driven by higher procurement volumes[24] - Total liabilities increased to CNY 193,804,912.82 from CNY 136,764,449.55, reflecting a growth of approximately 41.7%[39] - The company's equity increased to CNY 1,350,399,802.87 from CNY 1,246,517,642.42, representing an increase of about 8.3%[39] - The company’s non-current assets totaled CNY 317,415,834.25, an increase from CNY 295,752,868.47, reflecting a growth of about 7.4%[35] Cash Flow - Net cash flow from operating activities surged by 91.86% to CNY 108,468,516.56 year-on-year[12] - The net cash flow from operating activities for Q1 2021 was ¥108,468,516.56, up 92.0% from ¥56,536,247.50 in Q1 2020[53] - In Q1 2021, the company generated cash inflow from operating activities amounting to ¥208,978,913.99, a 83.3% increase compared to ¥114,155,116.03 in Q1 2020[51] - Cash and cash equivalents decreased to CNY 520,562,086.02 from CNY 944,198,841.72, a decline of approximately 44.7%[35] - The company experienced a net decrease in cash and cash equivalents of ¥430,127,658.49 in Q1 2021, contrasting with an increase of ¥58,630,670.66 in Q1 2020[55] Research and Development - R&D investment accounted for 12.48% of operating income, an increase of 2.76 percentage points compared to the previous year[12] - Research and development expenses surged by 143.98% to ¥21,113,198.05, reflecting increased investment in R&D projects[26] - Research and development expenses increased to ¥21,113,198.05 in Q1 2021, up 144.5% from ¥8,653,733.43 in Q1 2020[41] Shareholder Information - The number of shareholders at the end of the reporting period was 5,421[16] - The largest shareholder, MicroPort Endovascular CHINA Corp. Limited, holds 45.71% of the shares[16] Other Financial Information - The company reported a government subsidy of CNY 245,821.17 related to normal business operations[14] - Other receivables saw a dramatic increase of 4141.08% to ¥5,876,669.53, mainly due to income from unexpired financial products[24] - The company paid ¥33,240,633.29 in employee compensation in Q1 2021, which is a 52.5% increase from ¥21,832,607.98 in Q1 2020[51] - The total cash outflow for taxes in Q1 2021 was ¥26,863,814.90, up 95.2% from ¥13,769,928.84 in Q1 2020[51] - The company reported a credit impairment loss of -¥938,845.69 in Q1 2021, compared to -¥308,106.47 in Q1 2020[41] Market and Strategic Focus - The company is focused on expanding its market presence and developing new technologies in the medical sector[73]